Y-mAbs Therapeutics to Present At 39th Annual J.P. Morgan Healthcare ConferenceGlobeNewsWire • 01/06/21
Y-mAbs Signs License Agreement with SciClone for DANYELZA® (naxitamab-gqgk) and Omburtamab in ChinaGlobeNewsWire • 12/18/20
Y-mAbs Signs Distribution Agreement with Swixx for DANYELZA® (naxitamab-gqgk) and Omburtamab in Eastern EuropeGlobeNewsWire • 12/18/20
Y-mAbs and Takeda Announce Exclusive License and Distribution Agreement for DANYELZA® (naxitamab-gqgk) and Omburtamab in IsraelGlobeNewsWire • 12/04/20
FDA Approves Y-mAbs' DANYELZA® (naxitamab-gqgk) for the Treatment of NeuroblastomaGlobeNewsWire • 11/25/20
Y-mAbs Therapeutics, Inc. (YMAB) CEO Claus Moller on Q3 2020 Results - Earnings Call TranscriptSeeking Alpha • 11/08/20
Y-mAbs Announces FDA Clearance of IND for Lutetium-177 Labeled Omburtamab Antibody for Adult IndicationsGlobeNewsWire • 10/26/20
Y-mAbs’ Nivatrotamab for the Treatment of Patients with Neuroblastoma Granted Orphan Drug Designation and Rare Pediatric Disease Designation by FDAGlobeNewsWire • 10/07/20
Y-mAbs Therapeutics, Inc. (YMAB) CEO Claus Moller on Q2 2020 Results - Earnings Call TranscriptSeeking Alpha • 08/12/20
Y-mAbs Announces Second Quarter 2020 Financial Results and Recent Corporate DevelopmentsGlobeNewsWire • 08/06/20
Y-mAbs Announces Completion of Submission of Omburtamab Biologics License Application to FDAGlobeNewsWire • 08/06/20
Y-mAbs to Announce Second Quarter 2020 Financial and Operating Results on August 6, 2020GlobeNewsWire • 08/04/20
Y-mAbs Announces Update on SADA Technology and New Preclinical SADA ConstructGlobeNewsWire • 07/14/20
Y-mAbs Announces Initiation of Submission of Omburtamab Rolling Biologics License Application to the FDAGlobeNewsWire • 06/30/20